Close Menu

NEW YORK (GenomeWeb) – Proteomics International said today it has entered a strategic alliance with CPR Pharma Services focused on clinical trials and related research.

Under the terms of the deal, Proteomics International will acquire 10 percent of CPR's share capital in exchange for 4 million of its shares. This transaction is subject to CPR shareholder approval and is scheduled to take place on March 5, 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.